The Primary
Care Companionfor CNS Disorders

Schizophrenia/Schizoaffective Disorders

Original Research June 15, 2005

CME Article: The Relation Between Body Fat Distribution and Cardiovascular Risk Factors in Patients With Schizophrenia: A Cross-Sectional Pilot Study

Martha M. Lato; M. Beatriz Currier; Oscar Villaverde; Mercedes Gonzalez-Blanco

Prim Care Companion J Clin Psychiatry 2005;7(3):115-118

Article Abstract

Schizophrenia Weight Cardiovascular Health

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 26 • 2024 • Number 6

Read the Current Issue

Narrative Review

Dextromethorphan-Quinidine for Agitation in Dementia

Original Research

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Original Research

Intervention to Enhance Mental Health Competency

Original Research

Evolution of Treatment Modalities for PTSD

Rounds in the General Hospital

Etiology, Prevention, and Management of TD

Rounds in the General Hospital

Comorbid Bipolar Disorder and PTSD

View current Issue

Original Research

Olanzapine/Samidorphan Effects on Weight Gain

January 2, 2025

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over...

Christoph U. Correll, Michael J. Doane, David McDonnell, et al

Original Research

Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan

December 4, 2024

During up to 4 years of treatment, the combination of olanzapine/samidorphan was safe and well-tolerated, and patients’ symptoms remained stable.

Jacob S. Ballon, René S. Kahn, Christina Arevalo, et al

Original Research

Aripiprazole Lauroxil Initiation Regimens

August 12, 2024

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.

Roger W. Sommi, Stephen R. Saklad, Peter J. Weiden, et al

CME Article: The Relation Between Body Fat Distribution and Cardiovascular Risk Factors in Patients With Schizophrenia: A Cross-Sectional Pilot Study

Read the Current Issue

Dextromethorphan-Quinidine for Agitation in Dementia

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Intervention to Enhance Mental Health Competency

Evolution of Treatment Modalities for PTSD

Etiology, Prevention, and Management of TD

Comorbid Bipolar Disorder and PTSD

ELSEWHERE:

FOLLOW US:

CME Article: The Relation Between Body Fat Distribution and Cardiovascular Risk Factors in Patients With Schizophrenia: A Cross-Sectional Pilot Study

Read the Current Issue

Dextromethorphan-Quinidine for Agitation in Dementia

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Intervention to Enhance Mental Health Competency

Evolution of Treatment Modalities for PTSD

Etiology, Prevention, and Management of TD

Comorbid Bipolar Disorder and PTSD

Related Articles

Olanzapine/Samidorphan Effects on Weight Gain

Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan

Aripiprazole Lauroxil Initiation Regimens

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles